GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price traded up 2% on Thursday . The company traded as high as $9.40 and last traded at $9.28. 58,324 shares were traded during mid-day trading, a decline of 26% from the average session volume of 79,324 shares. The stock had previously closed at $9.10.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the company. Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, November 18th. JMP Securities restated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research note on Wednesday, November 20th.
Check Out Our Latest Analysis on GHRS
GH Research Price Performance
The stock has a market capitalization of $482.84 million, a P/E ratio of -11.75 and a beta of 0.74. The stock has a fifty day moving average price of $7.98 and a 200 day moving average price of $10.23.
GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Research analysts anticipate that GH Research PLC will post -0.79 earnings per share for the current year.
Hedge Funds Weigh In On GH Research
An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,966,726 shares of the company's stock after acquiring an additional 656,163 shares during the quarter. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP's holdings, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
